We’ll compare market approaches and results. The doctor perspective from: Daniel Palestrant, Sermo america Miguel Cabrer, Medting Spain Tim Ringrose, Doctors.net.uk UK Wellness 2.0 Tools – Consumer tools are an essential piece of the ongoing wellness 2.0 landscape. Many of the most sophisticated drug, treatment and condition tools are giving patients as much or even more information than their physicians. Their use has already been controversial in the US, but how is it playing out in different medical cultures across European countries? Isabelle Adenot, French National Order of Pharmacists France Roy Schoenberg, American Well america David Doherty, 3G Doctor Ireland Roni Zeiger, Google america Sabine Pinedo, stichting Begeleide Zelfzorg NL Neil Williams, Microsoft EU Mohammad Al-Ubaydli, Sufferers Know Best UK Joris Moolenaar, IPPZ NL Hospitals, Payers and Health 2.0 – A look at how hospitals and payers are getting together with doctors and individuals in the world of Health 2.0.0 – How is Health 2.0 affecting Pharma? A look at how pharmaceutical businesses are connecting with sufferers and doctors in brand-new ways, and how Health 2.0 is changing the way they’re conducting clinical research.0 – Discoveries and lessons from the meeting.These comprised death from cardiovascular causes, non-fatal myocardial infarction, coronary revascularization, or stroke. All primary events were validated by an unbiased event validation committee. Definitions of the major medical end points are given in the Methods section in the Supplementary Appendix, offered by NEJM.org. Secondary end points included components of the primary end point, assessed at 30 days and 12 months, and death from any cause, assessed at 12 months. Statistical Analysis Based on previous data,14,15 we estimated that 20 percent of participants in the control group could have key adverse cardiac or cerebral events within 12 months.